All sponsors

Shanghai Pharmaceuticals Holding Co., Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-32
RECRUITING8
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO88%

Delay Index: of 8 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +20.0 months). See all sponsors →

Open Shanghai Pharmaceuticals Holding Co., Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SPH4336 Tablets 400mg
NCT05744687
P2/3RecruitingLocally Advanced or Metastatic Breast Cancer3742026-05-31 (+21 mo)
T3011
NCT06214156
P1/2RecruitingAdvanced Melanoma422026-09-30 (+24 mo)
SPH4336 Tablets
NCT05860465
P2/3RecruitingLocally Advanced or Metastatic Breast Cancer2542026-12-01 (+21 mo)
LT3001 Drug:high dose
NCT05686642
P2RecruitingAcute Ischemic Stroke3002026-12-10 (+20 mo)
T3011 high dose
NCT06214143
P1/2RecruitingAdvanced Solid Tumors682026-12-31 (+12 mo)
SPH4336 Tablets
NCT05872347
P2RecruitingBreast Cancer Brain Metastases522026-12-31 (+12 mo)
SPH4336
NCT05944224
P1/2RecruitingAdvanced Solid Tumors632026-12-31 (+19 mo)
SPH5030
NCT06434597
P2RecruitingBiliary Tract or Colorectal Cancer With Her2-positive/Mutated602026-12-31
LT3001 Drug:high dose
NCT07754825
P2Not yet recruitingAcute Ischemic Stroke3002027-12-31